Richard P Butt
Overview
Explore the profile of Richard P Butt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Amerongen G, Siebenga P, Gurrell R, Dua P, Whitlock M, Gorman D, et al.
Br J Anaesth
. 2019 Mar;
123(2):e194-e203.
PMID: 30915991
Background: This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel α2/α3/α5 gamma-aminobutyric acid A (GABA) subunit selective partial positive allosteric modulator (PAM),...
2.
Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds D, DiVentura B, et al.
Neurology
. 2019 Mar;
92(15):e1786-e1795.
PMID: 30877186
Objective: The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABA receptors with minimal activity at α1-containing...
3.
Siebenga P, van Amerongen G, Okkerse P, Denney W, Dua P, Butt R, et al.
Eur J Pain
. 2019 Feb;
23(6):1129-1140.
PMID: 30793411
Background: Although reproducibility is considered essential for any method used in scientific research, it is investigated only rarely; thus, strikingly little has been published regarding the reproducibility of evoked pain...
4.
Gurrell R, Dua P, Feng G, Sudworth M, Whitlock M, Reynolds D, et al.
Pain
. 2018 May;
159(9):1742-1751.
PMID: 29787472
The effect of PF-06372865, a subtype-selective positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor, on chronic low back pain was investigated in a randomised, placebo- and active-controlled...
5.
McDonnell A, Collins S, Ali Z, Iavarone L, Surujbally R, Kirby S, et al.
Pain
. 2018 Mar;
159(8):1465-1476.
PMID: 29578944
The effect of PF-05089771, a selective, peripherally restricted Nav1.7 sodium channel blocker on pain due to diabetic peripheral neuropathy was investigated in a randomised, placebo and active-controlled parallel group clinical...
6.
Nickolls S, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown A, et al.
Br J Pharmacol
. 2017 Dec;
175(4):708-725.
PMID: 29214652
Background And Purpose: Benzodiazepines, non-selective positive allosteric modulators (PAMs) of GABA receptors, have significant side effects that limit their clinical utility. As many of these side effects are mediated by...
7.
Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, et al.
Br J Clin Pharmacol
. 2017 Nov;
84(2):301-309.
PMID: 29178434
Aim: Inhibitors of nerve growth factor (NGF) reduce pain in several chronic pain indications. NGF signals through tyrosine kinase receptors of the tropomyosin-related kinase (Trk) family and the unrelated p75...
8.
Swain N, Batchelor D, Beaudoin S, Bechle B, Bradley P, Brown A, et al.
J Med Chem
. 2017 Jul;
60(16):7029-7042.
PMID: 28682065
A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective Na1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving...
9.
Okkerse P, van Amerongen G, de Kam M, Stevens J, Butt R, Gurrell R, et al.
Br J Clin Pharmacol
. 2016 Nov;
83(5):976-990.
PMID: 27862179
Aim: The aim was to investigate the ability of a battery of pain models to detect analgesic properties of commonly used analgesics in healthy subjects. Methods: The battery consisted of...
10.
Alexandrou A, Brown A, Chapman M, Estacion M, Turner J, Mis M, et al.
PLoS One
. 2016 Apr;
11(4):e0152405.
PMID: 27050761
Human genetic studies show that the voltage gated sodium channel 1.7 (Nav1.7) is a key molecular determinant of pain sensation. However, defining the Nav1.7 contribution to nociceptive signalling has been...